Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30291447 | 1.00 | GAA (0.43) | GAACYP2C19PTGDRPRMT5WDR77 | |
| SCHEMBL30291577 | 0.87 | GAA (0.41) | GAACYP2C19PTGDRPRMT5WDR77 | |
| SCHEMBL30291479 | 0.86 | PIK3CD (0.49) | GAACYP2C19PRMT5WDR77PIK3CD | |
| SCHEMBL30291693 | 0.86 | PIK3CD (0.49) | GAACYP2C19PRMT5WDR77PIK3CD | |
| SCHEMBL29359142 | 0.83 | KIF18A (0.42) | PIK3CAACACBATRPIK3CB | |
| SCHEMBL22488000 | 0.81 | BRAF (0.46) | GAACYP2C19PIK3CABRAFATR | |
| SCHEMBL29355937 | 0.80 | PIK3CA (0.46) | GAACYP2C19PIK3CDPIK3CABRAF | |
| SCHEMBL22488002 | 0.80 | BRAF (0.43) | GAACYP2C19PIK3CABRAFATR | |
| SCHEMBL22488555 | 0.80 | BRAF (0.43) | GAACYP2C19PIK3CABRAFATR | |
| SCHEMBL13706046 | 0.77 | CYP2C19 (0.58) | GAACYP2C19OGAATRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | GAA 1754/4885CYP2C19 4217/4885PTGDR 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.